GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » ROE % Adjusted to Book Value

CVM (CEL-SCI) ROE % Adjusted to Book Value : -90.72% (As of Dec. 2024)


View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI ROE % Adjusted to Book Value?

CEL-SCI's ROE % for the quarter that ended in Dec. 2024 was -234.05%. CEL-SCI's PB Ratio for the quarter that ended in Dec. 2024 was 2.58. CEL-SCI's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -90.72%.

CEL-SCI ROE % Adjusted to Book Value Historical Data

The historical data trend for CEL-SCI's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI ROE % Adjusted to Book Value Chart

CEL-SCI Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.72 -11.35 -19.80 -31.67 -39.32

CEL-SCI Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.31 -29.74 -32.37 -43.62 -90.72

Competitive Comparison of CEL-SCI's ROE % Adjusted to Book Value

For the Biotechnology subindustry, CEL-SCI's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CEL-SCI's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CEL-SCI's ROE % Adjusted to Book Value falls into.


CEL-SCI ROE % Adjusted to Book Value Calculation

CEL-SCI's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-206.43% / 5.25
=-39.32%

CEL-SCI's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-234.05% / 2.58
=-90.72%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of CEL-SCI's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

CEL-SCI Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
PYPD MRNS PLUR EQ MLEC RLYB QTTB CALC PULM GDTC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
LSRM:Germany
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
Website
https://www.cel-sci.com
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Executives
Geert R Kersten director, officer: Chief Executive Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep officer: Sr. Vice President, Operations 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Robert Eugene Watson director 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano officer: Senior Vice President 8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Bruno Jean-marie Baillavoine director 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor officer: Chief Scientific Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman officer: Sr. Vice President, Research 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Clara Maximilian De director, officer: President
C Richard Kinsolving director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy director 8229 BOONE BLVD, STE 802, VIENNA VA 22182